Analysts are turning more bullish on the drug giant, investors are following progress across its drug pipeline, and there’s been renewed interest in Merck stock. The latest move reflects growing confidence that Merck can find new ways to generate revenue while staying in key treatment areas. For investors, the main story is not just the…

Continue Reading